Bakhtiar Ostadi | Competitive Advantage | Best Researcher Award

Published on by Scifat

Dr. Bakhtiar Ostadi | Competitive Advantage | Best Researcher Award 

Associate Professor at Tarbiat Modares University | Iran

Dr. Bakhtiar Ostadi is an Iranian scholar and Associate Professor of Industrial and Systems Engineering at Tarbiat Modares University, Tehran. With over two decades of academic and industrial contributions, he has advanced research in risk assessment, quality management, reliability engineering, and process improvement. He has authored numerous journal articles, conference papers, and books, and has supervised key projects in industries ranging from automotive and gas refineries to telecommunications and insurance. Fluent in English and Farsi, Dr. Ostadi integrates theoretical expertise with practical applications, making significant impacts in both academia and industry.

Profiles 

Scopus 

ORCID

Google Scholar

Educational Background

Dr. Bakhtiar Ostadi has a strong interdisciplinary academic foundation in mathematics and industrial engineering. He earned his Ph.D. in Industrial Engineering from Tarbiat Modares University, Tehran, Iran with a dissertation titled “An Examination of the Role of the Quality Management Systems in the Preparation and Implementation Stages of BPR Projects Using Concept of Dynamic Capabilities and RBVF Model.” Prior to that, he received his M.Sc. in Industrial Engineering from the University of Tehran, where his thesis focused on cost management in a flexible manufacturing system with an activity-based costing approach in the forging industry. His academic journey began with a B.Sc. in Applied Mathematics from K. N. Toosi University of Technology, Tehran.

Professional Experience

Dr. Bakhtiar Ostadi is currently an Associate Professor at the School of Industrial and Systems Engineering, Tarbiat Modares University, Tehran, Iran. He has led and participated in numerous research and industrial projects in areas such as process management, business process reengineering, reliability and risk engineering, and quality systems. His applied projects include activity-based costing in manufacturing industries, cargo train scheduling, risk management in civil and energy projects, evaluation of dependability in gas refineries, and developing excellence roadmaps for large-scale organizations such as Iran Insurance Company, IRIB, and MCI (Hamrah-e-Avval).

Dr. Bakhtiar Ostadi is an active educator and has taught a wide range of graduate and doctoral-level courses, including Reliability Engineering, Risk Reengineering, Quality and Process Improvement in Healthcare, Corporate Finance, Quality Engineering, Marketing Management, and Computer Simulation & Optimization. He also contributes to the scholarly community as a review board member of the International Journal of Production Research.

Research Interests

Dr. Bakhtiar Ostadi’s research interests cover a wide range of topics in industrial and systems engineering, reflecting both theoretical depth and practical application. He is particularly focused on data-driven risk assessment and pricing strategies for bidding, with an emphasis on improving decision-making under uncertainty. His work also extends to resilience engineering and quality engineering and management, aiming to enhance the robustness and efficiency of complex systems. In addition, he has a strong interest in process management, modeling, and simulation as tools for analyzing and optimizing organizational performance. Reliability engineering forms another key area of his expertise, where he explores methods to improve system dependability and maintenance practices. Complementing these technical domains, he also investigates customer value, customer experience, and marketing, integrating human and organizational dimensions into engineering solutions.

Publications

Using extended Monte Carlo simulation method for the improvement of risk management: Consideration of relationships between uncertainties

Year: 2007 | Citation: 159

Grouping evolution strategies: An effective approach for grouping problems

Year: 2015 | Citation: 66

Activity-based costing in flexible manufacturing systems with a case study in a forging industry

Year: 2008 | Citation: 64

A combined modelling of fuzzy logic and Time-Driven Activity-based Costing (TDABC) for hospital services costing under uncertainty

Year: 2019 | Citation: 60

An assessment model for hospital resilience according to the simultaneous consideration of key performance indicators: A system dynamics approach

Year: 2020 | Citation: 44

Conclusion

Dr. Bakhtiar Ostadi stands out as a highly accomplished researcher whose work embodies both innovation and practical impact. His career reflects a dedication to advancing industrial and systems engineering through risk management, resilience, and quality improvement. With his strong academic record, successful industrial projects, and commitment to education, he has established himself as a competitive candidate for the Best Researcher Award. By continuing to broaden his international collaborations and embracing emerging research trends, Dr. Ostadi is well positioned to achieve even greater global recognition. His contributions already make a lasting difference, and his future endeavors promise to further enhance the field.

MARIA JULIA MONTORO | Scientific research | Best Researcher Award

Published on by Scifat

Mrs. MARIA JULIA MONTORO – Scientific research  – Best Researcher Award

VALL HEBRON INSTITUTE OF ONCOLOGY | Spain

      Profiles

Scopus

ORCID

📍Current Position

Dr. Maria Julia Montoro Gómez is currently a Consultant in Haematology at the Hospital Universitari Vall d’Hebron in Barcelona, Catalonia, Spain. Since June 2013, she has been serving at this esteemed institution, where she focuses on myelodysplastic syndromes (MDS). Her professional category at the Institut Català de la Salut underscores her commitment to clinical hematology and therapeutic interventions. Dr. Montoro also plays a leadership role in the Hematological Genetic Counseling Unit, coordinating services for patients with Myeloid Neoplasms.

 

📝Publication Achievements 

With a passion for advancing research in hematology, Dr. Montoro has contributed significantly to the scientific community. She has a total of 27 publications, most of which are published in top-tier journals, including some in the first quartile and three in the first decile. Her work has been widely recognized, with over 315 citations and an H-index of 10, a remarkable achievement in the medical field. Two of her most notable publications came from her Ph.D. thesis, which earned the distinction of Cum Laude in 2019.

 

🔍Ongoing Research

Dr. Montoro’s ongoing research efforts continue to focus on myelodysplastic syndromes (MDS) and related hematologic conditions. In particular, her work delves into the molecular mechanisms of disease and therapeutic interventions. She has been part of cutting-edge studies on the prediction of response to lusparcept in MDS, collaborating with international leaders like Dr. Raza at the Herbert Irving Cancer Center, Columbia University. Dr. Montoro’s research aims to develop better strategies for prognostic evaluation and treatment personalization for patients with MDS.

 

🔬 Research Interests

Her key research interests lie in clinical medicine, therapeutics, healthcare, and the molecular mechanisms underlying disease progression in myeloid neoplasms. Specifically, Dr. Montoro is committed to finding better prognostic markers and treatment responses in hematological disorders. In addition, her interest in the genetics of hematological diseases is reflected in her role as the coordinator of the Hematological Genetic Counseling Unit at Vall d’Hebron.

 

🎓Academic Background

Dr. Montoro’s journey in medicine began with a Bachelor’s degree in Medicine and Surgery from the Universitat de València in 2008. She then completed her residency in Hematology and Hemotherapy at the Vall d’Hebron University Hospital from 2009 to 2013. Her academic excellence continued with a Ph.D. in Health Sciences from the Universitat Autònoma de Barcelona, where she defended her thesis titled “Improving strategies for the prognostic evaluation of Myelodysplastic Syndromes” with distinction. Dr. Montoro also pursued postgraduate studies in multiple linear regression at the Universitat Autònoma de Barcelona.

 

🏆Scholarships and Awards 

Throughout her career, Dr. Montoro has earned several prestigious scholarships and grants. She was awarded the Research Promotion Grant from the Spanish Foundation of Hematology and Hemotherapy consecutively in 2014 and 2015 for her project on the impact of autoimmune disorders in MDS patients. Additionally, she received a grant from the CRIS Foundation for her innovative research at Columbia University on terminal erythroid differentiation.

 

🧬Bioinformatics 

Dr. Montoro’s work incorporates advanced bioinformatics methodologies, especially in projects involving RNA sequencing and ex vivo systems to analyze cellular differentiation in MDS. These techniques are central to her research into predicting treatment responses and further advancing her understanding of the molecular mechanisms of these diseases.

 

🌐Professional Associations 

Dr. Montoro is a proud member of several leading hematology organizations, including the Vall d’Hebron Institute of Oncology (VHIO), the Spanish Society of Hematology and Hemotherapy (SEHH), the European Society of Hematology (EHA), and the Spanish Group of Myelodysplastic Syndromes (GESMD). Her active participation in these groups helps her stay at the forefront of new developments in oncology and hematology.

 

 📚Training & Workshops 

Dr. Montoro has an extensive portfolio of workshops and training sessions, including the V Jornadas de Investigadores del Grupo Andaluz de Síndromes Mielodisplásicos and the 3ª Edición: Next Generation Diagnosis in Leukemia, where she shared her expertise on hematologic neoplasms. She has also participated in various national and international congresses, presenting her research findings both as a principal author and co-author.

 

🎤Oral Presentations and🗣️Thought Leadership 

Throughout her career, Dr. Montoro has delivered 26 communications as a co-author and 10 as the principal author. Her oral presentations have addressed pivotal topics in myelodysplastic syndromes and have been well received at major conferences and workshops, further establishing her as a respected voice in the field.

 

🧑‍🔬Tasks Completed as a Researcher 

As a researcher, Dr. Montoro has completed a variety of tasks, from conducting clinical studies to engaging in translational research. She has led numerous projects focused on myelodysplastic syndromes, coordinated multicenter studies, and collaborated with international experts on innovative treatments.

 

🚀Success Factors 

Her success stems from a deep commitment to improving patient outcomes through a combination of clinical expertise and cutting-edge research. Dr. Montoro’s collaborative approach, combined with her drive to uncover the genetic basis of hematologic diseases, has solidified her reputation as a leader in her field.

 

🧪Publications & Laboratory Experience

Dr. Montoro’s laboratory experience includes significant work on cellular differentiation and molecular diagnostics in MDS. Her research has been published in top-tier journals, and her hands-on lab work has contributed to better prognostic evaluation strategies for MDS patients.

 

🔍 Conclusion

Dr. Maria Julia Montoro Gómez has had an exceptional career as an oncohematologist, with her research on myelodysplastic syndromes marking her as a leader in the field. Her dedication to both clinical practice and scientific research has earned her numerous awards, a strong presence in professional associations, and a prominent reputation in bioinformatics-driven medicine. Through her publications, presentations, and ongoing research, Dr. Montoro continues to make meaningful strides in improving patient outcomes and shaping the future of hematological care.

📚Publications

Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide

          Authors:  Serrano, G., Berastegui, N., Díaz-Mazkiaran, A., … Ezponda, T., Hernaez, M.

          Journal: Nature Communications,

Germline assessment for alloHSCT candidates over 50 years: A ‘Fast-Track’ screening in myeloid neoplasms

        Authors:  Torres-Esquius, S., Beas, F., Chen-Liang, T.H., … Montoro, M.J., Jerez, A.

        Journal: British Journal of Haematology, 

Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification

         Authors:  Mosquera Orgueira, A., Perez Encinas, M.M., Diaz Varela, N., … Díez Campelo, M., Valcárcel, D.

         Journal: British Journal of Haematology, 

Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion

        Authors:  Montoro, M.J., Palomo, L., Haferlach, C., … Haferlach, T., Valcárcel, D.

        Journal: Blood, 

Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes

       Authors:  Mosquera Orgueira, A., Perez Encinas, M.M., Diaz Varela, N.A., … Crucitti, D., Valcárcel, D.

       Journal: HemaSphere, 

       
   

Innovative Business Solutions Award

Published on by Scifat

Introduction: Welcome to the forefront of business innovation – the 'Innovative Business Solutions Award.' This esteemed accolade celebrates trailblazing individuals and organizations that have redefined industry standards through groundbreaking solutions. Join us in recognizing the pioneers of innovative business practices.

Award Eligibility: Open to businesses and individuals across industries, the 'Innovative Business Solutions Award' is designed for those who have demonstrated exceptional creativity and ingenuity in solving complex business challenges. There are no age limits, and nominees should showcase a track record of implementing innovative solutions.

Qualifications and Publications: Nominees should possess a strong business background with a focus on implementing innovative solutions. While academic qualifications are not mandatory, a proven track record of successfully implementing transformative business strategies will be a key consideration.

Recurrence and Evaluation Criteria: This annual award evaluates nominees based on the novelty and impact of their business solutions. Judges will consider the effectiveness of the solution in addressing specific challenges, the scalability of the innovation, and its contribution to the overall growth and sustainability of the business.

Submission Guidelines: Nominees are required to submit a comprehensive biography highlighting their role in the innovation, an abstract outlining the problem addressed and the solution implemented, and supporting files such as case studies, testimonials, or media coverage. Submissions must adhere to the guidelines provided on the online portal.

Recognition and Community Impact: Recipients of the award gain industry-wide recognition for their innovative business solutions. The 'Innovative Business Solutions Award' also emphasizes the positive impact nominees have on their communities, industries, and the broader business landscape.

Biography and Abstract: The biography should provide insights into the nominee's role in the innovation, highlighting key contributions and achievements. The abstract should succinctly describe the business challenge addressed, the innovative solution, and its impact.

Best Scholar Award

Published on by Scifat

Introduction: Welcome to the epitome of academic excellence – the 'Best Scholar Award.' This prestigious accolade honors individuals whose scholarly contributions have not only advanced knowledge but have also left an indelible mark on their respective fields. Join us in celebrating those who embody the spirit of relentless pursuit of knowledge and intellectual innovation.

Award Eligibility: The 'Best Scholar Award' is open to individuals aged 30 and above, recognizing seasoned scholars with a minimum of 15 years of academic experience. Nominees must hold a doctoral degree in their field and demonstrate a sustained commitment to scholarly pursuits.

Qualifications and Publications: Candidates are expected to possess a stellar academic background, showcasing excellence in research, teaching, and mentorship. Emphasis is placed on the quality and impact of publications, as well as their contribution to the advancement of knowledge in their discipline.

Recurrence and Evaluation Criteria: The 'Best Scholar Award' is an annual recognition. Evaluation criteria include the nominee's scholarly impact, research output, mentorship, and contributions to academic and professional communities. The emphasis is on originality, significance, and the lasting influence of the nominee's work.

Submission Guidelines: Nominees are required to submit a comprehensive biography highlighting their academic journey, an abstract summarizing their key contributions, and supporting files such as research papers, teaching materials, and commendations from peers. Submissions must be made through the online portal by the specified deadline.

Recognition and Community Impact: Recipients of the award not only gain recognition for their scholarly achievements but are also acknowledged for their positive influence on academic communities and their broader societal impact.

Biography and Abstract: The biography should encapsulate the nominee's academic journey, emphasizing key milestones and contributions. The abstract should provide a concise overview of the nominee's significant scholarly achievements, showcasing their impact on their field.